This page shows the latest Jivi news and features for those working in and with pharma, biotech and healthcare.
Another new entrant in the haemophilia A market is Bayer’s Jivi, which has a twice weekly dosing schedule. ... Hemlibra and Jivi are starting to make inroads into the wider haemophilia market in Europe, but Sobi remains confident that Elocta can also
The company in the midst of a rollout of its long-acting factor VIII product Jivi (damoctocog alfa pegol).
Jivi is another option in an increasingly crowded market for haemophilia A therapies, and Bayer is hoping that the new products dosing schedule will prove popular with patients and physicians. ... and Eloctate, and CSL Behring’s Afstyla, uptake
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...